INTRODUCTION {#s1}
============

Tailgut cysts, also called retrorectal cystic hamartomas, are rare, congenital lesions that arise from persistent remnants of the postanal gut ([@MCS003004ERDC30]; [@MCS003004ERDC24]; [@MCS003004ERDC28]). Half of all cases are asymptomatic. When symptomatic, the most common presentation includes pain, constipation, palpable rectal mass, infection with fistula, recurrent perianal sepsis, and urinary retention ([@MCS003004ERDC20]; [@MCS003004ERDC24]). Tailgut cysts are uncommon, but they are increasingly recognized after the largest series of 53 cases was published ([@MCS003004ERDC12]). Malignant transformation is rare but most likely to be adenocarcinoma with fewer cases of neuroendocrine tumors (NETs) reported ([@MCS003004ERDC1]). Two cases of metastatic NETs arising in a tailgut cyst have been published ([@MCS003004ERDC30]; [@MCS003004ERDC31]).

Genomic test results have not been published on tailgut cyst malignancies. Exome sequencing from small intestine NETs indicates a relatively low somatic mutation rate (∼0.1 variants/Mb) across a range of cancer genes ([@MCS003004ERDC6]) with a frameshift mutation in *CDKN1B* the most common in 8% of cases ([@MCS003004ERDC6]). RNA-based analysis of small intestine NETs includes the search for biomarkers ([@MCS003004ERDC22]) and expression profiling to identify subtypes ([@MCS003004ERDC15]; [@MCS003004ERDC3]). Recent work characterizing the RNA profile of single cells from intestinal organoids ([@MCS003004ERDC10]) represents initial steps toward molecular characterization of the diversity of neuroendocrine cells in healthy tissue ([@MCS003004ERDC7]), potentially enabling identification of NETs of unknown origin ([@MCS003004ERDC25]; [@MCS003004ERDC33]) and new therapeutic targets.

We present a case of retrorectal well-differentiated NET arising in a tailgut cyst with hepatic metastases. To our knowledge, this is the first up-front resection of both primary and metastatic disease and the first report using molecular assays to characterize the malignancy and identify the putative cell of origin.

RESULTS {#s2}
=======

A 77-yr-old man with a history of squamous cell carcinoma, prostate cancer, and melanoma presented with left hip pain radiating to the knee. A strong family history of cancer included a son with glioblastoma multiforme, father with prostate cancer, maternal aunt with lung cancer, maternal grandmother with ovarian cancer, and maternal grandfather with colon cancer. MRI of the spine was ordered because of suspected nerve compression causing sciatica. This detected a 6.3-cm presacral mass. CT similarly characterized a hypervascular presacral mass abutting the right bony pelvis and displacing the rectum ([Fig. 1](#MCS003004ERDF1){ref-type="fig"}A). It also showed two hypervascular hepatic lesions. FNA of the presacral mass showed a nest of epithelioid cells with delicate cytoplasm concerning for recurrent prostatic adenocarcinoma. However, immunohistochemical stains were strong for synaptophysin and weak for chromogranin, consistent with neuroendocrine differentiation. Overall, these findings were diagnostic of a well-differentiated NET with provisional WHO grade-1 based on Ki-67 index of \<1% and low mitotic index. As this is not a common site for a primary NET, it was unclear if this presacral mass represented a primary tumor or metastasis. Percutaneous biopsy of one hepatic lesion also showed well-differentiated NET with a provisional WHO grade-2 based on Ki-67 index 5.1%. Serum chromogranin, CEA, and CA 19-9 were within normal limits. Urine 5-HIAA was not performed given lack of hormonal symptoms.

![Imaging and histology of presacral mass. (*A*) Multiphasic CT demonstrating a hypervascular presacral mass (*white arrow*) measuring 4 × 6.3 × 4.6 cm. It displaces but does not appear to invade the adjacent rectum. (*B*) Presacral mass, 7 cm, firm and well-encapsulated, tethered to the sacrum, removed intact. (*C*) Well-differentiated neuroendocrine tumor component of presacral mass resection. H&E, 20× magnification. (*D*) Tailgut cyst component of presacral mass demonstrating lumina lined by prostatic-type and transitional epithelium with intervening fibrous tissue and disorganized smooth muscle. H&E, 20× magnification.](MCS003004Erd_F1){#MCS003004ERDF1}

Additional staging with novel somatostatin receptor scinitigraphy, Ga68 DOTATATE PET/CT revealed mild uptake in the pancreatic head in addition to the hepatic and presacral sites, compounding the location of the primary source. Pancreatic EUS with biopsy showed chronic pancreatitis with no clear tumor. Given that the disease was limited to the presacral mass and liver, a cytoreductive surgery was performed ([Fig. 1](#MCS003004ERDF1){ref-type="fig"}B). In the operating room, a long midline incision was used to allow access for both surgical teams. The liver resection was performed first to avoid any potential contamination from the colorectal portion of the operation. A 2-cm lesion in segment 4b and a 0.5-cm lesion in segment 3 were identified by intraoperative ultrasound and resected. Cholecystectomy was performed because the segment 4b lesion was close to the gallbladder fossa. The Colorectal team then mobilized the rectum and circumferentially dissected the tumor free. It was not invading any nearby structures. It was well-encapsulated and shelled out of the presacral space intact. The patient recovered on the regular surgical ward on the Early Recovery After Surgery (ERAS) pathway and was discharged to home on the third postoperative day.

Histology of the presacral mass showed nests and trabeculae of epithelioid cells with eosinophilic cytoplasm, stippled chromatin, and inconspicuous nucleoli consistent with a well-differentiated NET ([Fig. 1](#MCS003004ERDF1){ref-type="fig"}C). The Ki-67 staining within the primary tumor was 8.6% with \<1 mitosis/10 HPF consistent with WHO grade-2. The liver lesions showed identical morphologic features and were WHO grade-2 with a Ki-67 index of 6.4%. At the periphery of the presacral malignancy were multiple small cysts lined by a variety of epithelial cells including transitional, prostate-like, and mucinous epithelium ([Fig. 1](#MCS003004ERDF1){ref-type="fig"}D) with admixed bundles of smooth muscle and fibrous tissue diagnostic of a tailgut cyst, which harbored the primary NET.

Molecular testing was performed on the presacral mass, metastasis, germline, and plasma-derived DNA using both laboratory-grade and clinically available, CLIA-certified tests including Guardant360, FoundationOne, Stanford Tumor Actionable Mutation Panel (STAMP), and MyriadMyRisk. Mutations in BRCA1 E23fs\*17 (Germline Ashkenazi founder mutation; FoundationOne) and POM121L12 (variant of unknown significance; STAMP) were confirmed by exome sequencing. RNA sequencing was performed on biopsied ("Bx") and resected ("Rs") tissue from the sacral mass and liver. The expression levels in the samples are compared for the 25 most highly expressed genes in the presacral mass ([Fig. 2](#MCS003004ERDF2){ref-type="fig"}) and for the top 25 differentially expressed genes in the metastasis relative to normal liver ([Fig. 3](#MCS003004ERDF3){ref-type="fig"}). Tissue-specific gene expression was determined using the Genotype-Tissue Expression (GTEx) database of healthy tissue (The [@MCS003004ERDC11]) and indicated that many top genes were enriched in neuronal and/or endocrine tissues. Both gene lists showed characteristics of a NET with two of the top three genes, insulin-like 5 (*INSL5*) and chromogranin-B (*chrB*) common in both primary and metastasis. *INSL5*, a colon-specific marker of healthy gastrointestinal tract ([@MCS003004ERDC8]), and *CDH17* have both been linked to colorectal NETs ([@MCS003004ERDC21]; [@MCS003004ERDC32]; [@MCS003004ERDC8]; [@MCS003004ERDC29]). Classical neuroendocrine markers chromogranin-A and synaptophysin ([@MCS003004ERDC17]; [@MCS003004ERDC19]) and small intestine--specific markers secretogranins (SCG2 and SCG5) and somatostatin receptors SSTR1, 2, and 5 were all elevated ([@MCS003004ERDC22]; [@MCS003004ERDC16]; [@MCS003004ERDC3]). Gene ontology analysis indicated numerous pathways associated with signaling, secretory peptides, and extracellular vesicle trafficking, as expected for NETs ([Supplemental Tables S3, S4](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003004/-/DC1)). Pearson correlation coefficients of the gene expression between the core biopsies and resected tissues was 0.97 and 0.74 for normal liver and the metastasis, respectively ([Supplemental Fig. S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003004/-/DC1)), indicating the diagnostic potential of RNA sequencing from preoperative samples. See the Methods section for further details on sequencing SNV results and GTEx analysis.

![Gene expression for the top 25 genes in the presacral mass. Gene expression in fragments per kilobase per million (FPKM) in the presacral mass is sorted from high (blue) to low (white) and the top 25 genes compared in the three resected samples. Dominant Tissue indicates tissue-specific expression estimated from the GTEx database. EBV-Lymp represents expression associated with EBV-transformed lymphocytes. See the Methods section for details and top genes expressed in the metastasis ([Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003004/-/DC1)) and normal liver ([Supplemental Table S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003004/-/DC1)). An asterisk indicates sort column.](MCS003004Erd_F2){#MCS003004ERDF2}

![Gene expression for the top differentially expressed genes in the liver metastasis. Comparison of the gene expression (FPKM) in the top 25 genes with increased expression in the metastasis relative to normal liver, sorted from high (blue) to low (white). Genes are sorted by the average log~2~ of the fold change (FC) expression in the biopsied (Bx) and resected (Rs) samples. Dominant Tissue indicates tissue-specific expression estimated from the GTEx database. See Methods for details. An asterisk indicates sort column.](MCS003004Erd_F3){#MCS003004ERDF3}

To identify genes that distinguish the metastasis from the presacral mass, differential expression relative to the presacral mass is compared with differential expression relative to normal liver ([Fig. 4](#MCS003004ERDF4){ref-type="fig"}). Liver-specific genes are highly expressed in both the metastasis and normal liver with low expression in the presacral mass (e.g., *ALB*, *HP*, and *FGG* and other genes from [Supplemental Table S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003004/-/DC1) in the upper left quadrant). Genes highly expressed in the sacral mass ([Fig. 2](#MCS003004ERDF2){ref-type="fig"}) are also highly expressed in the metastasis with either low (e.g., *CHGB* and *INSL5* along the positive *x*-axis) or high (e.g., *B2M*, *ACTB*, and *HSP90B1* in the center of [Fig. 4](#MCS003004ERDF4){ref-type="fig"}) expression in the normal liver. Thirteen genes with high expression in the metastasis and low expression in both the presacral mass and normal liver tissue suggest that they are specific to the metastasis (set A in [Fig. 4](#MCS003004ERDF4){ref-type="fig"}; [Supplemental Table S10](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003004/-/DC1)). These genes have diverse roles in protein secretion (*LCN1* and *TCN1*), cell migration (*MYOC*), intracellular transport (*MARCH11* and *LY6H*), and differentiation (*NELL1* and *ASCL1*). Three of the genes have been associated with metastasis in the human cancer metastasis database (HCMDB): *HLA-G*, *MAGEA3* (melanoma), and the proto-oncogene *RET* (thyroid cancer; [@MCS003004ERDC34]). In addition, RET has been reported as a therapeutic target of tyrosine kinase inhibitors in small intestine NETs ([@MCS003004ERDC3]).

![Differential expression of the metastasis compared to the sacral mass and normal liver. Gene expression in the liver metastasis relative to the primary sacral mass (*y*-axis) is compared to the average expression in the metastasis relative to normal liver tissue (*x*-axis). Top genes that are highly expressed in the sacral mass ([Fig. 1](#MCS003004ERDF1){ref-type="fig"}), metastasis ([Fig. 2](#MCS003004ERDF2){ref-type="fig"}; [Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003004/-/DC1)), and normal liver ([Supplemental Table S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003004/-/DC1)) are shown as labels with color and shapes according to the dominant tissue; many genes do not meet the specificity requirements (*red squares*). Boxed labels indicate genes that are highly expressed in the metastasis compared with both the presacral mass and normal liver (set A) and decreased expression in the metastasis relative to the presacral mass (set B).](MCS003004Erd_F4){#MCS003004ERDF4}

Genes specific to the presacral mass (set B genes along the negative *y*-axis of [Fig. 4](#MCS003004ERDF4){ref-type="fig"}) have moderate expression (20--190 FPKM) but very low expression in the metastasis and normal liver ([Supplemental Table S10](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003004/-/DC1)). Many of these genes (including *FBLN1*, *DES*, *ACTG2*, *COMP*, *CNN1*, *MFAP5*, and *MYH11*) have roles in muscle/motility and the cytoskeleton. Two of the three most differentially expressed genes, *SFRP2* and *PRRX1*, were identified in the HCMDB database for metastases in melanoma and colorectal cancer. *SFRP2* and fibutlin-1 (*FBLN1*) are tumor-suppressor genes in colon ([@MCS003004ERDC18]) and gastric cancers ([@MCS003004ERDC4]), respectively. *PRRX1* induces the epithelial-to-mesenchymal transition, is required for cancer cells to metastasize in vivo, and is a biomarker for lack of metastasis ([@MCS003004ERDC23]). The reduced expression of these genes in the metastasis compared to the primary presacral mass may have contributed to progression to metastasis.

Expression levels of key genes in 12 different gastrointestinal enteroendocrine cells ([@MCS003004ERDC7]) were compared to determine a possible cell of origin for the presacral mass ([Table 1](#MCS003004ERDTB1){ref-type="table"}). Glucagon-like peptide 1 and 2 (*GLP1* and *GLP2*), oxyntomodulin, and glucagon (*GCG*) are all posttranslational modifications from the *Gcg* gene. The prohormone convertases (PCs) that generate these products are tissue-specific, with *PCSK2* found in pancreas, producing mostly glucagon, and *PCSK1* found in brain and intestine, producing mostly *GLP-1*, oxyntomodulin, and *GLP-2* ([@MCS003004ERDC27]). Greater than 100-fold higher levels of PCSK1 compared to *PCSK2* suggest that the *GCG* transcripts are likely *GLP1* and/or *GLP2* and not glucagon, consistent with intestinal L cells. High levels of *GCG* and pancreatic polypeptide (*PPY*) may be associated with an islet cell tumor in the pancreas; however, low expression of insulin (INS) and high expression of colorectal markers suggest that an L cell in the large intestine is the more likely cell of origin. Recent studies have shown that INSL5 is an orexigenic hormone released from colonic L cells in mice ([@MCS003004ERDC9]), supporting this hypothesis. High levels of nesftatin-1 suggest the A cell may be a candidate, but elevated levels in normal liver and low levels of ghrelin argue otherwise.

###### 

Gene expression (FPKM) in resected samples for enteroendocrine-specific genes in the gastrointestinal tract

  Cell type                                                          Hormone/precursor name                                            Gene     Liver   Sacral mass   
  ------------------------------------------------------------------ ----------------------------------------------------------------- -------- ------- ------------- -----
  K cells                                                            Gastric inhibitory peptide                                        *GIP*    0.0     0.0           0.0
  L cells                                                            Glucagon-like peptide 1; glucagon-like peptide 2; oxyntomodulin   *GCG*    1.1     113           687
  Pancreatic polypeptide                                             *PPY*                                                             3.5      313     250           
  Proprotein convertase subtilisin/kexin type 1                      *PCSK1*                                                           2.1      286     103           
  I cells                                                            Cholecystokinin                                                   *CCK*    0.0     0.0           0.1
  G cells                                                            Gastrin                                                           *GAST*   0.0     0.0           0.0
  Entero-chromaffin                                                  Tryptophan hyroxylase1 (serotonin)                                *TPH1*   0.0     0.3           0.2
  Tryptophan hyroxylase2 (serotonin)                                 *TPH2*                                                            0.0      6.1     0.8           
  Entero-chromaffin-like                                             Histidine decarboxylase (histidine production)                    *HDC*    0.6     0.0           0.2
  Vesicular monoamine transporter subtype 2 (histidine production)   *SLC18A2*                                                         11.1     6.4     9.8           
  N cell                                                             Neurotensin                                                       *NTS*    0.4     3.1           1.5
  S cells                                                            Secretin                                                          *SCT*    0.0     6.8           2.0
  P cells                                                            Leptin                                                            *LEP*    0.0     0.0           0.1
  M cells                                                            Motilin                                                           *MLN*    0.0     0.0           6.3
  D cells                                                            Somatostatin                                                      *SST*    0.0     0.3           3.8
  A cells (X-like)                                                   Ghrelin                                                           *GHRL*   0.0     0.4           0.8
  Nesfatin-1                                                         *NUCB2*                                                           62       317     274           

DISCUSSION {#s3}
==========

Most NETs arise in the gastrointestinal tract and lungs. Because there is no apparent source of neuroendocrine cells in the presacral space, many of these tumors likely derive from the glandular epithelium of tailgut cysts ([@MCS003004ERDC13]). This entity is not widely known but should be on the differential of any presacral mass. Gene expression provided a detailed description consistent with traditional pathological results and pointed toward a more detailed understanding of the tumor including a putative cell of origin that may provide a basis for future targeted therapies. Tumor heterogeneity was not assessed in this work, but transcriptomic analysis from the biopsy and resected tissue of both the primary and metastasis were highly similar and may indicate a promising source of diagnostic information in NETs.

METHODS {#s4}
=======

Sample Processing {#s4a}
-----------------

Tissue from needle core biopsies of the liver metastasis and adjacent normal was transferred to 1.5-ml Eppendorf tubes, placed on dry ice, and stored at −80°C. After 51 d the presacral mass and liver metastasis were resected and bulk samples from each were obtained. Bulk normal liver was obtained from a dark red piece of liver ∼0.5 cm from the white metastasis border. Normal tissue from the periphery of the metastasis was removed before incubating all three samples in prechilled RNA overnight at 4°C and then stored at −20°C until use. DNA and RNA were purified from all five samples using an AllPrep DNA/RNA Mini Kit (QIAGEN). DNA and RNA concentration was determined with via fluorimetry (Qubit) and the quality of RNA assessed via RIN number using electrophoresis (Agilent Bioanalyzer).

DNA Sequencing {#s4b}
--------------

CLIA-approved testing was performed using Guarant360, FoundationOne, STAMP, and MyriadMyRisk and verified via exome sequencing in our laboratory (Alizadeh). Pre- and postoperative testing of circulating cell-free DNA by Guardant360 revealed mutations in *ARID1A* and *SRC*. FoundationOne testing of both the primary presacral mass and liver metastasis showed mutations in *BRCA1* E23fs\*17 and *ASXL1* E635fs\*15. STAMP testing of the presacral mass and liver revealed variant of unknown significance (VUS) LRRTM4, which is the same as FoundationOne ASXL1. STAMP of the liver metastasis revealed another VUS, in POM121L12. Germline testing by MyriadMyRisk confirmed the *BRCA1* E23fs\*17 mutation (Ashkenazi founder mutation). For exome sequencing, Illumina sequencing libraries were constructed from sheared tumor DNA and matched normal from peripheral blood mononuclear cells using KAPA HyperPrep kit. Libraries were pooled and exomes enriched using SeqCapEZ MedExome (Roche NimbleGen) kit. The final product was sequenced with 150-bp paired-end reads on an Illumina HiSeq4000 to a median depth of ∼160× with an on-target rate of ∼88% for each library (See [Supplemental Table S5](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003004/-/DC1)). Variant calling and annotation were performed as previously described ([@MCS003004ERDC14]). Exome sequencing verifies the *BRCA1* germline mutation (from FoundationOne) and *POM121L12* (from STAMP); other mutations, including *LRRTM4* (from STAMP), *ASXL1* (from FoundationOne), and *ALK*, *ARID1A*, and *SRC* (from Guardant), were not supported. High allele fraction mutations detected by exome sequencing but none of the other assays include a homozygous *PCDHB16* missense mutation and other coding mutations in *SHANK2*, *SAMHD1*, *TNFSF8* (*CD30L*), and *NETO2*. See [Supplemental Table S6](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003004/-/DC1) for a summary of the assay results and Table S11 for all PASS filter variants from exome sequencing.

RNA Sequencing and Analysis {#s4c}
---------------------------

RNA-seq Illumina libraries were constructed from each sample using the SMARTer Stranded Total RNA Sample Prep Kit---HI Mammalian (Clonetech \#634873) kit and 43--69 million 75-bp paired-end sequencing reads obtained on the Illumina NextSeq500 (see [Table 2](#MCS003004ERDTB2){ref-type="table"} for details). Reads were aligned using STAR ([@MCS003004ERDC5]) to the hg19 genome. Ht-Seq ([@MCS003004ERDC2]) using stringent assignments was used to count uniquely mapped reads to each gene ([Supplemental Table S9](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003004/-/DC1)). Fragments per kilobase of transcript length per million reads (FPKM) values were determined for each gene by normalizing the counts by the total number of mapped reads in the sample, the length of the gene in base pairs and scaling by 1 × 10^9^ ([Supplemental Table S7](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003004/-/DC1)). Results for the top 25 most highly expressed genes for the resected presacral mass, liver metastasis, and normal liver can be found in [Figure 2](#MCS003004ERDF2){ref-type="fig"}, [Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003004/-/DC1), and [Supplemental Table S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003004/-/DC1), respectively.

###### 

RNA sequencing metrics

      Sample                       Total RNA (ng)   PF clusters
  --- ---------------------------- ---------------- -------------
  1   Normal liver, biopsy         344              47,443,335
  2   Normal liver, resected       800              43,283,705
  3   Liver metastasis, biopsy     620              69,793,317
  4   Liver metastasis, resected   800              57,589,019
  5   Sacral mass, resected        800              46,676,100

Similarity between the gene expression profiles for the five samples was determined by calculating the Pearson correlation coefficient between the gene expression values of the top 1000 genes for each pair of samples ([Supplemental Fig. S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003004/-/DC1)). The resected liver metastasis and sacral mass are highly correlated (0.93), and both are less correlated to the biopsied liver metastasis (0.74 and 0.66, respectively). The two normal samples are highly correlated with each other (0.97), moderately correlated to the biopsied liver metastasis (0.74 and 0.7, respectively), and weakly correlated to the resected metastasis and sacral mass (0.2--0.3). Scatter plots of the 1000 most highly expressed genes ([Supplemental Fig. S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003004/-/DC1)) indicate that both normal liver samples contain liver-specific genes (as determine by GTEx, see below), and the biopsied metastasis sample contains a population of liver genes, which are not seen in the resected metastasis or sacral mass, and which explain the reduced correlation between these samples. The metastasis biopsy has a component of normal liver that is lower in the resected sample and negligible in the sacral mass.

Tissue Specificity Analysis {#s4d}
---------------------------

Tissue specificity was determined from the GTEx database ([@MCS003004ERDC11]) by converting the raw count data for each sample to FPKM. The average expression across all samples for each gene and tissue combination was then calculated and tabulated such that each gene corresponds to a vector of tissue expression levels. Original GTEx tissue labels are truncated at the dash ("-") in the tissue name such that compartments within an organ are ignored, for example "Brain - Cerebellum" and "Brain - Cortex" are both "Brain." A gene is classified as specific if the most abundant tissue contains at least 10% of the total expression and the second most abundant tissue has at least twofold lower abundance than the top tissue. In the resected liver sample, the 25 genes with the highest expression ([Supplemental Table S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003004/-/DC1)) include known liver genes such as albumin, haptoglobin, and several apolipoproteins. Four genes did not pass the threshold for tissue specificity, but the remaining 21 were all determined to be specific for liver. Two liver genes are also highly expressed in the sacral mass: transthyretin (*TTR*), which is reported to transport thyroid hormone, and tumor protein translationally controlled 1 (*TPT1*), which is involved in calcium binding and microtubule stabilization ([@MCS003004ERDC26]).

Gene Ontology {#s4e}
-------------

Gene ontology annotations were determined by importing the top 100 gene names for the sacral mass and top 100 differentially expressed genes in the liver metastasis into the DAVID functional analysis tool (<https://david.ncifcrf.gov/>). Pathways with Bonferroni adjusted P-values of \<0.01 for the top genes are reported for the sacral mass ([Supplemental Table S3](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003004/-/DC1)) and liver metastasis ([Supplemental Table S4](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003004/-/DC1)).

Differentially Expressed Genes between Normal Liver and Metastasis {#s4f}
------------------------------------------------------------------

The log~2~ of the FC in differential expression for each gene is calculated as $$\log_{2}({FC}) = \left\langle {{{lo}g_{2}}\left( \frac{x_{{Met},i} + x_{0}}{x_{{Normal},i} + x_{0}} \right)} \right\rangle_{i},$$ where *x* is the gene expression in FPKM, *x*~0~ = 1 FPKM to minimize the impact of low abundance transcripts, and the average is over both samples in the metastasis and normal liver (i.e., *i* = {Biopsy, Resected}). Differentially expressed genes were ranked by averaging the log~2~(FC) values from resected and biopsied samples and the top 25 genes with increased expression between normal liver and the metastasis reported ([Fig. 3](#MCS003004ERDF3){ref-type="fig"}). Several of these top genes have not been reported as neuroendocrine markers but are consistent with neuroendocrine functions and/or tumor metastasis. *VEGF* is a growth factor active in angiogenesis, vasculogenesis, and endothelial cell growth and is up-regulated in many tumors ([@MCS003004ERDC26]). *SCGB2A1* is a secretoblobin that is preferentially expressed in the cervix. It binds androgens and other steroids and has been associated with ovarian cancer ([@MCS003004ERDC26]). Trefoil factor 1 (*TFF1*) is a secretory protein expressed in healthy gastrointestinal mucosa of the stomach as well as in tumors ([@MCS003004ERDC26]). Peptide YY (*PYY*) inhibits pancreatic secretion and mobility in the gut. In the GTEx database glutaminyl-peptide cyclotransferase (*QPCT*) is expressed in several neuroendocrine tissues (adrenal gland, pituitary, and hypothalamus) and is responsible for the presence of pyroglutamyl residues in many neuroendocrine peptides ([@MCS003004ERDC26]). Eight of the genes in [Figure 3](#MCS003004ERDF3){ref-type="fig"} are determined to be specific for neural and/or endocrine-related tissues including brain (*SCG3*, *PPP1R1B*, *KIF5C*, and *ADCYAP1*), pituitary (*CHGB* and *PCKS1N*), and pancreas (*PPY* and *GCG*). Mucin 13 (MUC13) is a secreted cell surface glycoprotein expressed by ductal and glandular epithelial tissues and may play a role in cell signaling ([@MCS003004ERDC26]). MUC13 is not specific to a single tissue, but it is expressed primarily in colon and small intestine ([@MCS003004ERDC11]). Gene ontology annotations indicate processes associated with secreted proteins, signaling peptides, and extracellular regions, similar to the sacral mass ([Supplemental Table S4](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003004/-/DC1)). Full names for genes in [Figures 2](#MCS003004ERDF2){ref-type="fig"} and [3](#MCS003004ERDF3){ref-type="fig"} can be found in [Supplemental Table S8](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003004/-/DC1).

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

The table of RNA-seq gene counts is available as [Supplemental Material](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003004/-/DC1) but raw sequencing data is not available under the IRB used to perform this work.
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